Movement Alert｜HBM HOLDINGS-B Rises 7.4% in Regular Trading, AI-Powered Antibody Language Model and Multiple Catalysts Continue to Drive Momentum

Market Focus09-21

On September 21, HBM HOLDINGS-B rose 7.4% in regular trading, reaching HKD 14.48 per share with turnover of HKD 22.59 million, extending a multi-session rally fueled by a cluster of positive developments.

The latest catalyst stems from the company's wholly-owned subsidiary Nona Biotech, which on September 16 announced the successful development of HCAbLM — the world's first language model trained on fully human heavy-chain-only antibodies. Built on a dataset of 31.8 million sequences from 73 independently immunized transgenic mice, HCAbLM captures unique sequence grammar that conventional antibody models fail to detect, marking a significant milestone in applying AI to antibody discovery and development.

Fundamentally, the company reported H1 revenue of USD 122 million, up 20.9% year-over-year, with a gross margin of approximately 95%. Molecule licensing and collaboration revenue rose to USD 113 million. Additionally, partner Solstice Oncology completed a USD 225 million Series A to advance porustobart in colon cancer, while partner Windward Bio reported positive Phase II interim data for HBM9378 in asthma and initiated Phase III trials. The company's inclusion in the Hang Seng Composite Index and Stock Connect eligibility effective September 7 further broadens its investor base.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment